Fundies.
English

Insider transactions

EDGAR

Acumen Pharmaceuticals, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-15.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
48 transactions, 305,128 shares
Sum of shares × price per share: 625,430.9287

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 91

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-06-17 Filed 2026-06-17Porter Derrell Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock		Acquired (A)13,0401.07
13,952.8

Derived: shares × price per share. Exact value 13952.80.

48,540Direct (D) No— Open filing 0001628280-26-043987 Read from the filing’s XML Dispute this row
2026-06-17 Filed 2026-06-17Porter Derrell Director
S

Open market or private sale of non-derivative or derivative security

Common Stock		Disposed (D)13,0402.325
30,318

Derived: shares × price per share. Exact value 30318.000.

35,500Direct (D) No— Open filing 0001628280-26-043987 Read from the filing’s XML Dispute this row
2026-06-17 Filed 2026-06-17Porter Derrell Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (13,040) — exercise price 1.07		Disposed (D)13,0400—0Direct (D) No
F2
  • F2 The shares subject to the option vested in full on the date of the 2026 annual stockholder meeting.
Open filing 0001628280-26-043987 Read from the filing’s XML Dispute this row
2026-06-16 Filed 2026-06-17Porter Derrell Director
S

Open market or private sale of non-derivative or derivative security

Common Stock		Disposed (D)12,8002.326
29,772.8

Derived: shares × price per share. Exact value 29772.800.

35,500Direct (D) No
F1
  • F1 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.305 to $2.345. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001628280-26-043987 Read from the filing’s XML Dispute this row
2026-06-15 Filed 2026-06-17Porter Derrell Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock		Acquired (A)6,4601.07
6,912.2

Derived: shares × price per share. Exact value 6912.20.

54,760Direct (D) No— Open filing 0001628280-26-043987 Read from the filing’s XML Dispute this row
2026-06-15 Filed 2026-06-17Porter Derrell Director
S

Open market or private sale of non-derivative or derivative security

Common Stock		Disposed (D)6,4602.345
15,148.7

Derived: shares × price per share. Exact value 15148.700.

48,300Direct (D) No— Open filing 0001628280-26-043987 Read from the filing’s XML Dispute this row
2026-06-15 Filed 2026-06-17Porter Derrell Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (6,460) — exercise price 1.07		Disposed (D)6,4600—13,040Direct (D) No
F2
  • F2 The shares subject to the option vested in full on the date of the 2026 annual stockholder meeting.
Open filing 0001628280-26-043987 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-10Fountain Nathan B Director
S

Open market or private sale of non-derivative or derivative security

Common Stock		Disposed (D)6,4002.2301
14,272.64

Derived: shares × price per share. Exact value 14272.6400.

48,150Direct (D) No
F1
  • F1 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.2300 to $2.2311. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001628280-26-042280 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Fountain Nathan B Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock		Acquired (A)35,5000—54,550Direct (D) No
F1
  • F1 Represents a restricted stock unit (RSU) award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Open filing 0001628280-26-041281 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Fountain Nathan B Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (53,250) — exercise price 2.29		Acquired (A)53,2500—53,250Direct (D) No
F2
  • F2 The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Open filing 0001628280-26-041281 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Stalfort John A III Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock		Acquired (A)35,5000—220,624Direct (D) No
F1
  • F1 Represents a restricted stock unit (RSU) award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Open filing 0001628280-26-041273 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Stalfort John A III Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (53,250) — exercise price 2.29		Acquired (A)53,2500—53,250Direct (D) No
F2
  • F2 The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Open filing 0001628280-26-041273 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Stoppel Laura Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock		Acquired (A)35,5000—48,300Direct (D) No
F1, F2
  • F1 Represents a restricted stock unit (RSU) award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
  • F2 Under the Reporting Person's arrangement with RA Capital Management, L.P. (the Adviser), the Reporting Person holds the option and RSUs for the benefit of the RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus Fund II, L.P. (the Nexus Fund II) and a separately managed account (the Account). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement of the RSUs, as applicable, which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock.
Open filing 0001628280-26-041263 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Stoppel Laura Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (53,250) — exercise price 2.29		Acquired (A)53,2500—53,250Direct (D) No
F3, F2
  • F3 The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
  • F2 Under the Reporting Person's arrangement with RA Capital Management, L.P. (the Adviser), the Reporting Person holds the option and RSUs for the benefit of the RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus Fund II, L.P. (the Nexus Fund II) and a separately managed account (the Account). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement of the RSUs, as applicable, which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock.
Open filing 0001628280-26-041263 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Drapkin Kimberlee C Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock		Acquired (A)35,5000—48,300Direct (D) No
F1
  • F1 Represents a restricted stock unit (RSU) award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Open filing 0001628280-26-041276 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Drapkin Kimberlee C Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (53,250) — exercise price 2.29		Acquired (A)53,2500—53,250Direct (D) No
F2
  • F2 The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Open filing 0001628280-26-041276 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Golumbeski George Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock		Acquired (A)35,5000—35,500Direct (D) No
F1
  • F1 Represents a restricted stock unit (RSU) award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Open filing 0001628280-26-041268 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Golumbeski George Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (53,250) — exercise price 2.29		Acquired (A)53,2500—53,250Direct (D) No
F2
  • F2 The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Open filing 0001628280-26-041268 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Ives Jeffrey L. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock		Acquired (A)35,5000—48,300Direct (D) No
F1
  • F1 Represents a restricted stock unit (RSU) award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Open filing 0001628280-26-041270 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Ives Jeffrey L. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (53,250) — exercise price 2.29		Acquired (A)53,2500—53,250Direct (D) No
F2
  • F2 The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Open filing 0001628280-26-041270 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Porter Derrell Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock		Acquired (A)35,5000—48,300Direct (D) No
F1
  • F1 Represents a restricted stock unit (RSU) award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Open filing 0001628280-26-041272 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Porter Derrell Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (53,250) — exercise price 2.29		Acquired (A)53,2500—53,250Direct (D) No
F2
  • F2 The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Open filing 0001628280-26-041272 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerRA Capital Nexus Fund II, L.P. DirectorKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock		Acquired (A)35,5000—48,300Indirect (I) See footnotesNo
F1, F2, F3
  • F1 Represents a restricted stock unit (RSU) award to Laura Stoppel. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to Dr. Stoppel's continuous service through such vesting date.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus Fund II, L.P. (the Nexus Fund II) and a separately managed account (the Account). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky, and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Under Dr. Stoppel's arrangement with the Adviser, Dr. Stoppel holds the RSUs and the option for the benefit of the Fund, the Nexus Fund II and the Account. Dr. Stoppel is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement of the RSUs, as applicable, which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the RSUs, the option and the underlying common stock.
Open filing 0001231919-26-000604 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerRA Capital Nexus Fund II, L.P. DirectorKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (53,250) — exercise price 2.29		Acquired (A)53,2500—53,250Indirect (I) See FootnotesNo
F7, F2, F3
  • F7 Represents the award of an option to Dr. Stoppel. The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to Dr. Stoppel's continuous service through such vesting date.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus Fund II, L.P. (the Nexus Fund II) and a separately managed account (the Account). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky, and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Under Dr. Stoppel's arrangement with the Adviser, Dr. Stoppel holds the RSUs and the option for the benefit of the Fund, the Nexus Fund II and the Account. Dr. Stoppel is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement of the RSUs, as applicable, which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the RSUs, the option and the underlying common stock.
Open filing 0001231919-26-000604 Read from the filing’s XML Dispute this row
2026-03-16 Filed 2026-03-18RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerRA Capital Nexus Fund II, L.P. DirectorKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock		Acquired (A)6,060,6063.30
19,999,999.8

Derived: shares × price per share. Exact value 19999999.80.

19,103,785Indirect (I) See footnotesNo
F1, F2
  • F1 Held directly by RA Capital Healthcare Fund, L.P. (the Fund).
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for the Fund, RA Capital Nexus Fund II, L.P. (the Nexus Fund II) and a separately managed account (the Account). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky, and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
Open filing 0001231919-26-000262 Read from the filing’s XML Dispute this row
2026-03-06 Filed 2026-03-10Meisner Derek M Officer: Chief Legal Officer Corp Sec
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock		Acquired (A)2,0901.85
3,866.5

Derived: shares × price per share. Exact value 3866.50.

176,089Direct (D) Yes— Open filing 0001628280-26-016645 Read from the filing’s XML Dispute this row
2026-03-06 Filed 2026-03-10Meisner Derek M Officer: Chief Legal Officer Corp Sec
S

Open market or private sale of non-derivative or derivative security

Common Stock		Disposed (D)2,0903.26
6,813.4

Derived: shares × price per share. Exact value 6813.40.

173,999Direct (D) Yes
F1
  • F1 The reported sales occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025.
Open filing 0001628280-26-016645 Read from the filing’s XML Dispute this row
2026-03-06 Filed 2026-03-10Meisner Derek M Officer: Chief Legal Officer Corp Sec
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (2,090) — exercise price 1.85		Disposed (D)2,0900—71,048Direct (D) Yes
F2
  • F2 The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.
Open filing 0001628280-26-016645 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-03Meisner Derek M Officer: Chief Legal Officer Corp Sec
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock		Acquired (A)9,4061.85
17,401.1

Derived: shares × price per share. Exact value 17401.10.

183,405Direct (D) Yes— Open filing 0001628280-26-014365 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-03Meisner Derek M Officer: Chief Legal Officer Corp Sec
S

Open market or private sale of non-derivative or derivative security

Common Stock		Disposed (D)9,4063.0099
28,311.1194

Derived: shares × price per share. Exact value 28311.1194.

173,999Direct (D) Yes
F1, F2
  • F1 The reported sales occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025.
  • F2 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $3.0000 to $3.0300. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001628280-26-014365 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-03Meisner Derek M Officer: Chief Legal Officer Corp Sec
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (9,406) — exercise price 1.85		Disposed (D)9,4060—73,138Direct (D) Yes
F3
  • F3 The shares subject to the employee stock option vest in 48 equal monthly installments starting on the date the option was granted, such that the option will be fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.
Open filing 0001628280-26-014365 Read from the filing’s XML Dispute this row
2026-01-28 Filed 2026-01-28Meisner Derek M Officer: Chief Legal Officer Corp Sec
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock		Acquired (A)2,6711.85
4,941.35

Derived: shares × price per share. Exact value 4941.35.

176,670Direct (D) Yes— Open filing 0001628280-26-003948 Read from the filing’s XML Dispute this row
2026-01-28 Filed 2026-01-28Meisner Derek M Officer: Chief Legal Officer Corp Sec
S

Open market or private sale of non-derivative or derivative security

Common Stock		Disposed (D)2,6713.0016
8,017.2736

Derived: shares × price per share. Exact value 8017.2736.

173,999Direct (D) Yes
F1, F2
  • F1 The reported sales occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025.
  • F2 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $3.0000 to $3.0100. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001628280-26-003948 Read from the filing’s XML Dispute this row
2026-01-28 Filed 2026-01-28Meisner Derek M Officer: Chief Legal Officer Corp Sec
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (2,671) — exercise price 1.85		Disposed (D)2,6710—82,544Direct (D) Yes
F3
  • F3 The shares subject to the employee stock option vest in 48 equal monthly installments starting on the date the option was granted, such that the option will be fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.
Open filing 0001628280-26-003948 Read from the filing’s XML Dispute this row
2026-01-26 Filed 2026-01-28Meisner Derek M Officer: Chief Legal Officer Corp Sec
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock		Acquired (A)15,0851.85
27,907.25

Derived: shares × price per share. Exact value 27907.25.

189,084Direct (D) Yes— Open filing 0001628280-26-003948 Read from the filing’s XML Dispute this row
2026-01-26 Filed 2026-01-28Meisner Derek M Officer: Chief Legal Officer Corp Sec
S

Open market or private sale of non-derivative or derivative security

Common Stock		Disposed (D)15,0853.0005
45,262.5425

Derived: shares × price per share. Exact value 45262.5425.

173,999Direct (D) Yes
F1, F2
  • F1 The reported sales occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025.
  • F2 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $3.0000 to $3.0100. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001628280-26-003948 Read from the filing’s XML Dispute this row
2026-01-26 Filed 2026-01-28Meisner Derek M Officer: Chief Legal Officer Corp Sec
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (15,085) — exercise price 1.85		Disposed (D)15,0850—85,215Direct (D) Yes
F3
  • F3 The shares subject to the employee stock option vest in 48 equal monthly installments starting on the date the option was granted, such that the option will be fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.
Open filing 0001628280-26-003948 Read from the filing’s XML Dispute this row
2026-01-23 Filed 2026-01-23Meisner Derek M Officer: Chief Legal Officer Corp Sec
S

Open market or private sale of non-derivative or derivative security

Common Stock		Disposed (D)5,6331.9027
10,717.9091

Derived: shares × price per share. Exact value 10717.9091.

173,999Direct (D) No
F3, F4
  • F3 Represents the number of shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025.
  • F4 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.8800 to $1.9400. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001628280-26-003349 Read from the filing’s XML Dispute this row
2026-01-22 Filed 2026-01-23Meisner Derek M Officer: Chief Legal Officer Corp Sec
S

Open market or private sale of non-derivative or derivative security

Common Stock		Disposed (D)1,0541.84
1,939.36

Derived: shares × price per share. Exact value 1939.36.

179,632Direct (D) No
F1
  • F1 Represents the number of shares sold by the Reporting Person through an automatic sell to cover transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 15, 2024.
Open filing 0001628280-26-003349 Read from the filing’s XML Dispute this row
2026-01-22 Filed 2026-01-23OConnell Daniel Joseph Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock		Disposed (D)2,6891.8838
5,065.5382

Derived: shares × price per share. Exact value 5065.5382.

881,275Direct (D) No
F1, F3
  • F1 Represents the number of shares sold by the Reporting Person through an automatic sell to cover transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2024.
  • F3 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.8700 to $1.9000. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001628280-26-003346 Read from the filing’s XML Dispute this row
2026-01-22 Filed 2026-01-23Zuga Matt Officer: CFO Chief Business Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock		Disposed (D)1,6871.86
3,137.82

Derived: shares × price per share. Exact value 3137.82.

304,924Direct (D) No
F1
  • F1 Represents the number of shares sold by the Reporting Person through an automatic sell to cover transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024.
Open filing 0001628280-26-003347 Read from the filing’s XML Dispute this row
2026-01-22 Filed 2026-01-23Siemers Eric Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock		Disposed (D)8951.82
1,628.9

Derived: shares × price per share. Exact value 1628.90.

255,371Direct (D) No
F1
  • F1 Represents the number of shares sold by the Reporting Person through an automatic sell to cover transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2024.
Open filing 0001628280-26-003348 Read from the filing’s XML Dispute this row
2026-01-22 Filed 2026-01-23Barton Russell Officer: Chief Operating Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock		Disposed (D)4621.84
850.08

Derived: shares × price per share. Exact value 850.08.

205,092Direct (D) No
F1
  • F1 Represents the number of shares sold by the Reporting Person through an automatic sell to cover transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024.
Open filing 0001628280-26-003344 Read from the filing’s XML Dispute this row
2026-01-21 Filed 2026-01-23Meisner Derek M Officer: Chief Legal Officer Corp Sec
S

Open market or private sale of non-derivative or derivative security

Common Stock		Disposed (D)2,2471.8083
4,063.2501

Derived: shares × price per share. Exact value 4063.2501.

180,686Direct (D) No
F1, F2
  • F1 Represents the number of shares sold by the Reporting Person through an automatic sell to cover transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 15, 2024.
  • F2 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7600 to $1.8700. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001628280-26-003349 Read from the filing’s XML Dispute this row
2026-01-21 Filed 2026-01-23OConnell Daniel Joseph Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock		Disposed (D)9,3461.8112
16,927.4752

Derived: shares × price per share. Exact value 16927.4752.

883,964Direct (D) No
F1, F2
  • F1 Represents the number of shares sold by the Reporting Person through an automatic sell to cover transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2024.
  • F2 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7600 to $1.8800. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001628280-26-003346 Read from the filing’s XML Dispute this row
2026-01-21 Filed 2026-01-23Zuga Matt Officer: CFO Chief Business Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock		Disposed (D)2,4731.8072
4,469.2056

Derived: shares × price per share. Exact value 4469.2056.

306,611Direct (D) No
F1, F2
  • F1 Represents the number of shares sold by the Reporting Person through an automatic sell to cover transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024.
  • F2 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7650 to $1.8700. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001628280-26-003347 Read from the filing’s XML Dispute this row
2026-01-21 Filed 2026-01-23Siemers Eric Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock		Disposed (D)2,3311.8035
4,203.9585

Derived: shares × price per share. Exact value 4203.9585.

256,266Direct (D) No
F1, F2
  • F1 Represents the number of shares sold by the Reporting Person through an automatic sell to cover transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2024.
  • F2 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7600 to $1.8700. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001628280-26-003348 Read from the filing’s XML Dispute this row
2026-01-21 Filed 2026-01-23Barton Russell Officer: Chief Operating Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock		Disposed (D)2,3151.806
4,180.89

Derived: shares × price per share. Exact value 4180.890.

205,554Direct (D) No
F1, F2
  • F1 Represents the number of shares sold by the Reporting Person through an automatic sell to cover transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024.
  • F2 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7600 to $1.8700. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001628280-26-003344 Read from the filing’s XML Dispute this row
2026-01-20 Filed 2026-01-21OConnell Daniel Joseph Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock		Acquired (A)299,8000—893,310Direct (D) No
F1
  • F1 Represents a restricted stock unit (RSU) award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date.
Open filing 0001628280-26-002962 Read from the filing’s XML Dispute this row
2026-01-20 Filed 2026-01-21OConnell Daniel Joseph Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (450,000) — exercise price 1.86		Acquired (A)450,0000—450,000Direct (D) No
F2
  • F2 The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.
Open filing 0001628280-26-002962 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 7,211 filings read, the latest filed 2026-11-13. Prior quarter ending 2026-06-30: 9,150 filings read.

Showing 1–50 of 73

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Sands Capital Alternatives, LLC 3,720,105 SH8,258,633 dollarsUnchanged Prior quarter: 3,720,105Open filing 0001846444-26-000013 Filed 2026-11-13 Dispute this row
BlackRock, Inc. Partly reported under another manager2,802,028 SH6,220,502 dollarsHigher by 311,913 Prior quarter: 2,490,115Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
FRANKLIN TEMPLETON INC Partly reported under another manager2,305,096 SH498,592 dollarsUnchanged Prior quarter: 2,305,096Open filing 0000038777-26-000291 Filed 2026-11-12 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 1,816,442 SH4,032,501 dollarsHigher by 144,370 Prior quarter: 1,672,072Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
Knollwood Investment Advisory, LLC 1,628,510 SH3,615,292 dollarsUnchanged Prior quarter: 1,628,510Open filing 0001999346-26-000006 Filed 2026-11-13 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager1,154,919 SH2,564,361 dollarsHigher by 13,061 Prior quarter: 1,141,858Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
Hudson Bay Capital Management LP 1,025,000 SH2,275,500 dollarsHigher by 70,000 Prior quarter: 955,000Open filing 0001393825-26-000083 Filed 2026-11-13 Dispute this row
Pathstone Holdings, LLC 859,110 SH1,907,224 dollarsUnchanged Prior quarter: 859,110Open filing 0002011612-26-000005 Filed 2026-11-13 Dispute this row
STATE STREET CORP Partly reported under another manager837,120 SH1,858,406 dollarsHigher by 236,592 Prior quarter: 600,528Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager614,654 SH1,364,532 dollarsLower by 60,371 Prior quarter: 675,025Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
ACADIAN ASSET MANAGEMENT LLC Partly reported under another manager341,825 SH754 dollarsHigher by 71,487 Prior quarter: 270,338Open filing 0001140361-26-042753 Filed 2026-11-09 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager323,999 SH719,403 dollarsHigher by 32,440 Prior quarter: 291,559Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 323,420 SH717,992 dollarsHigher by 2,625 Prior quarter: 320,795Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
VANGUARD FIDUCIARY TRUST CO 291,201 SH646,466 dollarsLower by 39 Prior quarter: 291,240Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
Hudson Bay Capital Management LP Option: Call 200,000 SH444,000 dollarsNot in the prior quarter’s filings read Open filing 0001393825-26-000083 Filed 2026-11-13 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager114,999 SH255,297 dollarsLower by 9,378 Prior quarter: 124,377Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
PFG Investments, LLC 107,151 SH237,875 dollarsHigher by 12,901 Prior quarter: 94,250Open filing 0001754960-26-000997 Filed 2026-11-12 Dispute this row
CATALYST FINANCIAL PARTNERS LLC 99,699 SH221,332 dollarsHigher by 10,000 Prior quarter: 89,699Open filing 0001927537-26-000005 Filed 2026-11-06 Dispute this row
MORGAN STANLEY Partly reported under another manager89,226 SH198,081 dollarsLower by 47,537 Prior quarter: 136,763Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
Empowered Funds, LLC Partly reported under another manager86,389 SH191,784 dollarsNot in the prior quarter’s filings read Open filing 0001592828-26-000008 Filed 2026-11-13 Dispute this row
FMR LLC Partly reported under another manager76,488 SH169,803 dollarsHigher by 68,958 Prior quarter: 7,530Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
RHUMBLINE ADVISERS 74,134 SH164,570 dollarsHigher by 39,100 Prior quarter: 35,034Open filing 0001115418-26-000015 Filed 2026-11-10 Dispute this row
Nuveen, LLC Partly reported under another manager68,385 SH151,815 dollarsHigher by 5,030 Prior quarter: 63,355Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
SIMPLEX TRADING, LLC 62,600 SH138,972 dollarsNot in the prior quarter’s filings read Open filing 0001488542-26-000013 Filed 2026-11-04 Dispute this row
Prospera Financial Services Inc Partly reported under another manager52,500 SH11,030 dollarsHigher by 2,500 Prior quarter: 50,000Open filing 0001541625-26-000004 Filed 2026-11-04 Dispute this row
BARCLAYS PLC Partly reported under another manager48,650 SH108,003 dollarsHigher by 8,995 Prior quarter: 39,655Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row
DEUTSCHE BANK AG\ Partly reported under another manager40,169 SH89,175 dollarsLower by 5,963 Prior quarter: 46,132Open filing 0000948046-26-000083 Filed 2026-11-06 Dispute this row
AMERICAN CENTURY COMPANIES INC Partly reported under another manager38,824 SH86,189 dollarsHigher by 14,688 Prior quarter: 24,136Open filing 0000748054-26-000008 Filed 2026-11-12 Dispute this row
PFG Investments, LLC Option: Call 32,400 SH31,150 dollarsNot in the prior quarter’s filings read Open filing 0001754960-26-000997 Filed 2026-11-12 Dispute this row
Intrepid Financial Planning Group LLC 30,150 SH66,933 dollarsUnchanged Prior quarter: 30,150Open filing 0001214659-26-013983 Filed 2026-11-12 Dispute this row
UBS Group AG Partly reported under another manager24,622 SH54,660 dollarsLower by 1,143 Prior quarter: 25,765Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Invesco Ltd. Partly reported under another manager24,282 SH53,906 dollarsLower by 306 Prior quarter: 24,588Open filing 0000914208-26-000462 Filed 2026-11-12 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager22,534 SH50,589 dollarsHigher by 2,373 Prior quarter: 20,161Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
Spark Investment Management LLC 21,700 SH48,174 dollarsHigher by 7,000 Prior quarter: 14,700Open filing 0000899140-26-001312 Filed 2026-11-13 Dispute this row
GROUP ONE TRADING LLC Option: Call 19,800 SH43,956 dollarsLower by 63,600 Prior quarter: 83,400Open filing 0000932540-26-000017 Filed 2026-11-10 Dispute this row
Police Firemen's Retirement System of New Jersey Partly reported under another manager19,393 SH43,052 dollarsUnchanged Prior quarter: 19,393Open filing 0002040686-26-000007 Filed 2026-11-09 Dispute this row
STIFEL FINANCIAL CORP Partly reported under another manager19,275 SH42,791 dollarsHigher by 6,375 Prior quarter: 12,900Open filing 0000720672-26-000017 Filed 2026-11-12 Dispute this row
Independent Advisor Alliance 19,000 SH42,180 dollarsUnchanged Prior quarter: 19,000Open filing 0001062993-26-005882 Filed 2026-11-10 Dispute this row
Pinnacle Wealth Management Advisory Group, LLC 18,021 SH40,007 dollarsHigher by 1 Prior quarter: 18,020Open filing 0001631864-26-000006 Filed 2026-10-23 Dispute this row
PINNACLE ASSOCIATES LTD 18,021 SH40,007 dollarsHigher by 1 Prior quarter: 18,020Open filing 0000743127-26-000005 Filed 2026-10-20 Dispute this row
Factor Wealth Management LTD 16,500 SH36,630 dollarsUnchanged Prior quarter: 16,500Open filing 0001754960-26-000821 Filed 2026-10-08 Dispute this row
Vanguard Global Advisers, LLC 15,655 SH34,754 dollarsHigher by 8,971 Prior quarter: 6,684Open filing 0001811242-26-000017 Filed 2026-11-13 Dispute this row
JANE STREET GROUP, LLC Option: Put Partly reported under another manager13,500 SH29,970 dollarsNot in the prior quarter’s filings read Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
Quantinno Capital Management LP 12,345 SH27,406 dollarsLower by 14,424 Prior quarter: 26,769Open filing 0001759654-26-000011 Filed 2026-11-13 Dispute this row
BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager11,921 SH26,465 dollarsHigher by 592 Prior quarter: 11,329Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row
SEI INVESTMENTS CO Partly reported under another manager11,564 SH25,672 dollarsUnchanged Prior quarter: 11,564Open filing 0000350894-26-000059 Filed 2026-11-10 Dispute this row
Mesirow Financial Investment Management, Inc. 11,305 SH25,097 dollarsUnchanged Prior quarter: 11,305Open filing 0001469475-26-000005 Filed 2026-11-05 Dispute this row
Bronte Capital Management Pty Ltd. 10,716 SH23,790 dollarsUnchanged Prior quarter: 10,716Open filing 0001471085-26-000007 Filed 2026-11-12 Dispute this row
Steward Partners Investment Advisory, LLC 10,006 SH22,213 dollarsHigher by 6 Prior quarter: 10,000Open filing 0001723397-26-000006 Filed 2026-11-13 Dispute this row
OSAIC HOLDINGS, INC. Partly reported under another manager7,350 SH16,384 dollarsUnchanged Prior quarter: 7,350Open filing 0001677044-26-000011 Filed 2026-11-12 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • RA CAPITAL MANAGEMENT, L.P. 20,992,669 SH
  • Alyeska Investment Group, L.P. 2,454,754 SH
  • ADAR1 Capital Management, LLC 2,111,334 SH
  • Ikarian Capital, LLC 1,053,797 SH
  • TWO SIGMA INVESTMENTS, LP 622,882 SH
  • NORTHERN TRUST CORP 360,744 SH
  • BANK OF AMERICA CORP /DE/ 274,781 SH
  • BOOTHBAY FUND MANAGEMENT, LLC 273,012 SH
  • NOMURA HOLDINGS INC 189,712 SH
  • GOLDMAN SACHS GROUP INC 183,927 SH
  • BRIDGEWAY CAPITAL MANAGEMENT, LLC 176,171 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 126,104 SH
  • Sixth Street Partners Management Company, L.P. 115,099 SH
  • CHARLES SCHWAB INVESTMENT MANAGEMENT INC 115,099 SH
  • MILLENNIUM MANAGEMENT LLC 60,598 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 59,400 SH
  • Squarepoint Ops LLC 52,351 SH
  • CITADEL ADVISORS LLC 51,049 SH
  • WELLS FARGO COMPANY/MN 49,686 SH
  • MARSHALL WACE, LLP 48,114 SH
  • Verdad Advisers, LP 44,478 SH
  • PRICE T ROWE ASSOCIATES INC /MD/ 39,327 SH
  • Qube Research Technologies Ltd 38,614 SH
  • NEW YORK STATE COMMON RETIREMENT FUND 36,200 SH
  • Rangeley Capital, LLC 35,000 SH
  • XTX Topco Ltd 32,134 SH
  • Y-Intercept (Hong Kong) Ltd 29,540 SH
  • AXQ CAPITAL, LP 24,426 SH
  • MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 21,761 SH
  • Virtu Financial LLC 11,940 SH
  • TWO SIGMA SECURITIES, LLC 11,892 SH
  • Balyasny Asset Management L.P. 11,872 SH
  • INTECH INVESTMENT MANAGEMENT LLC 10,446 SH
  • Integrated Wealth Concepts LLC 10,179 SH
  • Legal General Group Plc 4,610 SH
  • Tower Research Capital LLC (TRC) 2,899 SH
  • ROYAL BANK OF CANADA 1,561 SH
  • MERCER GLOBAL ADVISORS INC /ADV 200 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
RA Capital Management, L.P. Common Stock, $0.0001 par value per share29.521,101,669.0003/13/2026 Filed 2026-03-17SCHEDULE 13D/AAmendment 4Open filing 0001104659-26-029538 Dispute this row
Peter Kolchinsky Common Stock, $0.0001 par value per share29.521,101,669.0003/13/2026 Filed 2026-03-17SCHEDULE 13D/AAmendment 4Open filing 0001104659-26-029538 Dispute this row
Rajeev Shah Common Stock, $0.0001 par value per share29.521,101,669.0003/13/2026 Filed 2026-03-17SCHEDULE 13D/AAmendment 4Open filing 0001104659-26-029538 Dispute this row
RA Capital Healthcare Fund, L.P. Common Stock, $0.0001 par value per share26.819,103,785.0003/13/2026 Filed 2026-03-17SCHEDULE 13D/AAmendment 4Open filing 0001104659-26-029538 Dispute this row
Franklin Resources, Inc. Common stock, par value $0.0001 per share3.82,305,096.0009/30/2025 Filed 2025-11-04SCHEDULE 13G/AAmendment 1Open filing 0000038777-25-000217 Dispute this row
Charles B. Johnson Common stock, par value $0.0001 per share00.0009/30/2025 Filed 2025-11-04SCHEDULE 13G/AAmendment 1Open filing 0000038777-25-000217 Dispute this row
Rupert H. Johnson, Jr. Common stock, par value $0.0001 per share00.0009/30/2025 Filed 2025-11-04SCHEDULE 13G/AAmendment 1Open filing 0000038777-25-000217 Dispute this row
Sands Capital Alternatives, LLC Common Stock, par value $0.0001 per share5.63,417,075.0006/30/2025 Filed 2025-08-13SCHEDULE 13G/AAmendment 2Open filing 0001846444-25-000017 Dispute this row
Sands Capital Ventures Discovery Fund III, L.P. Common Stock, par value $0.0001 per share1.91,124,729.0006/30/2025 Filed 2025-08-13SCHEDULE 13G/AAmendment 2Open filing 0001846444-25-000017 Dispute this row
Sands Capital Global Venture Fund II, L.P. Common Stock, par value $0.0001 per share1.91,146,173.0006/30/2025 Filed 2025-08-13SCHEDULE 13G/AAmendment 2Open filing 0001846444-25-000017 Dispute this row
Sands Capital Life Sciences Pulse Fund, LLC Common Stock, par value $0.0001 per share1.91,146,173.0006/30/2025 Filed 2025-08-13SCHEDULE 13G/AAmendment 2Open filing 0001846444-25-000017 Dispute this row
SANDS FRANK M. Common Stock, par value $0.0001 per share5.63,417,075.0006/30/2025 Filed 2025-08-13SCHEDULE 13G/AAmendment 2Open filing 0001846444-25-000017 Dispute this row
James B. Murray Jr. Common Stock, $0.0001 par value per share5.003,611,36004/04/2025 Filed 2026-04-07SCHEDULE 13GOpen filing 0001140361-26-013660 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,024,280 filings read, dated 2004-06-14 to 2026-11-13: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
20151
2016204,322
2017202,494
2018202,048
2019193,638
2020144,184
2021224,474
202240,015
2023199,811
2024117,969
2025235,520
2026254,026

Filings made before the SEC required XML are listed, not extracted.

Back to Acumen Pharmaceuticals, Inc.